

1 **Appendix:**

2 **Biparatopic Nanobodies protect mice from lethal challenge with SARS-CoV-2**  
3 **variants of concern**

4  
5 Teresa R. Wagner<sup>1,2\*</sup>, Daniel Schnepf<sup>3\*</sup>, Julius Beer<sup>3\*</sup>, Natalia Ruetalo<sup>4\*</sup>, Karin Klingel<sup>5</sup>, Philipp  
6 D. Kaiser<sup>2</sup>, Daniel Junker<sup>2</sup>, Martina Sauter<sup>5</sup>, Bjoern Traenkle<sup>2</sup>, Desiree I. Frecot<sup>1,2</sup>, Matthias  
7 Becker<sup>2</sup>, Nicole Schneiderhan-Marra<sup>2</sup>, Annette Ohnemus<sup>3</sup>, Martin Schwemmle<sup>3,6</sup>, Michael  
8 Schindler<sup>4</sup>, Ulrich Rothbauer<sup>1,2,7#</sup>

9

10 Addresses

11 <sup>1</sup> Pharmaceutical Biotechnology, Eberhard Karls University, Tübingen, Germany

12 <sup>2</sup> NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany

13 <sup>3</sup> Institute of Virology, Medical Center University Freiburg, Freiburg, Germany

14 <sup>4</sup> Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen,  
15 Tübingen, Germany

16 <sup>5</sup> Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany

17 <sup>6</sup> Faculty of Medicine, University of Freiburg, Freiburg, Germany

18 <sup>7</sup> Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor  
19 Therapies", Eberhard Karls University, Tübingen, Germany

20

21 \* authors contributed equally to this work

22 # corresponding author

23

24 Correspondence:

25 Prof. Dr. Ulrich Rothbauer, NMI Natural and Medical Sciences Institute at the University of  
26 Tübingen

27 Markwiesenstr. 55, 72770 Reutlingen, Germany.

28 E-mail: [ulrich.rothbauer@uni-tuebingen.de](mailto:ulrich.rothbauer@uni-tuebingen.de)

29 Phone: +49 7121 51530-415

30 Fax: +49 7121 51530-816

31 Orcid ID: 0000-0001-5923-8986

32

33

34	<b>Table of Content</b>	
35		
36	<b>Appendix Tables.....</b>	<b>4</b>
37	Appendix Table S1. Nb combinations for bipNbs .....	4
38	Appendix Table S2. Primer Sequences.....	5
39		
40		

41 **Appendix Tables**

42 **Appendix Table S1. Nb combinations for bipNbs**

<b>Biparatopic (Bip)/ bivalent Nb</b>	<b>Single Nb combination</b>
NM1267	NM1230-(G <sub>4</sub> S) <sub>4</sub> -NM1226
NM1268	NM1228-(G <sub>4</sub> S) <sub>4</sub> -NM1226
NM1251 (Control)	Pep-Nb-(G <sub>4</sub> S) <sub>4</sub> -Pep-Nb

43

44

45 **Appendix Table S2. Primer Sequences**

<b>Primer</b>	<b>Sequence 5'-3'</b>
NM1228Nfor	GGACGTCTCAACTCTGACGTGCAGCTGGTGGAAAT
NM1228Nrev	CACCACCGCCAGATCCACCGCCACCTGATCCTCCGCCTCCTGAGGACACGGTGACCAGGGACCC
NM1226Cfor	GGTGGATCTGGCGGTGGTGGAAAGTGGTGGCGGAGGTAGTCAGGTGCAGCTGGTGGAAAT
NM1226Crev	GGGGAATTCAGTGATGGTGATGGTGGTGTGAGGACACGGTGACCGGGGCC
RBDfor	ATATCTAGAGCCACCATGTTTCGTGTTTCTGG
RBDrev	AAGATCTGCTAGCTCGAGTCGC
N501Yfor	GGCTTTCAGCCACATATGGCGTGGGCTATCAGC
N501Yrev	CCACGCCATATGTGGGCTGAAAGCCGTAG
L452Rfor	GGCAACTACAATTACCGGTACCGGCTGTTCCGGAAG
L452Rrev	CGGTACCGGTAATTGTAGTTGCCGCCG
V367Ffor	CGACTACTCCTTCCTGTACAACCTCCGCCAGCTTC
V367Frev	CGGAGTTGTACAGGAAGGAGTAGTCGGCCACGCA
T478Kfor	CCGGCAGCAAGCCTTGTAACGGCGTGGAAG
T478Krev	CGTTACAAGGCTTGCTGCCGGCCTGATAGA
E484Kfor	GTAACGGCGTGAAAGGCTTCAACTGCTACTTCCC
E484Krev	GCAGTTGAAGCCTTTCACGCCGTTACAAGGGGT
K417Nfor	GACAGACAGGCAACATCGCCGACTACAAC TACAAGC
K417Nrev	GTTGTAGTCGGCGATGTTGCCTGTCTGTCCAGGG
K417Tfor	GACAGACAGGCACCATCGCCGACTACAAC TACAAG
K417Trev	GTTGTAGTCGGCGATGGTGCCTGTCTGTCCAGGGG

46